Host blood protein biomarkers to screen for tuberculosis disease: a systematic review and meta-analysis

• Published in: Journal of clinical microbiology 2024-11, Vol.62 (11), p.e0078624
• Main Authors: Gaeddert, Mary, Glaser, Kerstin, Chendi, Bih H, Sultanli, Ayten, Koeppel, Lisa, MacLean, Emily L, Broger, Tobias, Denkinger, Claudia M
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; Blood Proteins - analysis; Child; Epidemiology; Humans; Mass Screening - methods; Mycobacteriology and Aerobic Actinomycetes; Sensitivity and Specificity; Tuberculosis - blood; Tuberculosis - diagnosis
• ISSN: 0095-1137; 1098-660X; 1098-660X
• DOI: 10.1128/jcm.00786-24

Non-sputum tests are needed to improve tuberculosis (TB) diagnosis and close the diagnostic gap. The World Health Organization's target product profile (TPP) for point-of-care (POC) screening tests requires a minimum sensitivity of 90% and a specificity of 70%. Our objective was to identify host blood protein biomarkers meeting TPP criteria. A systematic review was conducted and reported following PRISMA guidelines. Data extraction and quality assessment with Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) were completed for the included studies. Heterogeneity was assessed. For biomarkers reporting sensitivity and specificity in at least four studies, a random-effects meta-analysis was performed for biomarkers with similar cut-offs. We screened 4,651 citations and included 65 studies that enrolled 16,010 participants and evaluated 156 host proteins. Most (47/65) studies enrolled adult pulmonary TB (PTB), with 15 studies in adult extra-pulmonary TB and 5 in children. Small early-stage discovery studies with case-control design were common (24/65) and had a high risk of bias. For adult PTB, CRP, IP-10, NCAM-1, and SAA met TPP criteria in high-quality studies. There was a high degree of heterogeneity in biomarker cut-offs and study design. CRP at 10 mg/L cut-off was meta-analyzed from 10 studies; pooled sensitivity 86% [95% confidence interval (CI): 80-95] and pooled specificity 67% (95% CI: 54-79). In people living with HIV (six studies), CRP pooled sensitivity was 93% (95% CI: 90-95), and pooled specificity was 59% (95% CI: 40-78). We identified promising biomarkers that performed well in high-quality studies. Data overall are limited and highly heterogenous. Further standardized validation across subgroups in prospective studies is needed before translating into POC assays. To our knowledge, this is the first comprehensive systematic review of host blood protein biomarkers for tuberculosis (TB), and we identified promising biomarkers for a TB screening test.